Dianthus Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DNTH and other ETFs, options, and stocks.

About DNTH

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies.

CEO

Marino Garcia

CEOMarino Garcia

Employees

Employees78

Headquarters

New York, New York

HeadquartersNew York, New York

Founded

2015

Founded2015

Employees

Employees78

DNTH Key Statistics

Market cap

577.59M

Market cap577.59M

Price-Earnings ratio

-6.21

Price-Earnings ratio-6.21

Dividend yield

—

Dividend yield—

Average volume

276.96K

Average volume276.96K

High today

$18.75

High today$18.75

Low today

$17.40

Low today$17.40

Open price

$18.73

Open price$18.73

Volume

286.15K

Volume286.15K

52 Week high

$32.27

52 Week high$32.27

52 Week low

$13.37

52 Week low$13.37

Analyst ratings

100%

of 12 ratings

Buy

100%

Hold

Sell

People also own

Based on the portfolios of people who own DNTH. This list is generated using Robinhood data, and it’s not a recommendation.

Dianthus Therapeutics

Why Robinhood?

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. Show more

DNTH Key Statistics

Analyst ratings

100%

People also own

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies.